Compare · INCR vs MRK
INCR vs MRK
Side-by-side comparison of Intercure Ltd. (INCR) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCR and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $283.29B, about 4981.5x INCR ($56.9M).
- Over the past year, INCR is down 29.8% and MRK is up 46.6% - MRK leads by 76.4 points.
- MRK has hit the wire 29 times in the past 4 weeks while INCR has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- Intercure Ltd.
- Merck & Company Inc.
- Price
- $1.13+6.60%
- $114.77-0.80%
- Market cap
- $56.9M
- $283.29B
- 1M return
- +22.83%
- +1.46%
- 1Y return
- -29.81%
- +46.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 29
- Recent ratings
- 1
- 25
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest INCR
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
- SEC Form 20-F filed by Intercure Ltd.
- SEC Form 3 filed by new insider Rabinovich Alexander
- SEC Form 3 filed by new insider Michelson Lennie Grinbaum
- SEC Form 3 filed by new insider Granot Alon Shmuel
- SEC Form 3 filed by new insider Salton David
- SEC Form 3 filed by new insider Cohen Amos
- SEC Form 3 filed by new insider Hirschfeld Gideon
- SEC Form 6-K filed by Intercure Ltd.
Latest MRK
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
- SEC Form 4 filed by Director Lavizzo-Mourey Risa J